Abbott Laboratories (ABT.N)
83.61USD
6:40pm BST
$0.19 (+0.23%)
$83.42
$83.14
$83.92
$83.09
272,414
1,526,583
$83.92
$60.32
About
Overall
| Beta: | 1.09 |
| Market Cap(Mil.): | $147,168.00 |
| Shares Outstanding(Mil.): | 1,764.18 |
| Dividend: | 0.32 |
| Yield (%): | 1.53 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 56.14 | 32.41 | 37.25 |
| EPS (TTM): | 1.49 | -- | -- |
| ROI: | 4.39 | 13.47 | 12.15 |
| ROE: | 8.45 | 66.93 | 16.99 |
Abbott device helps in cutting blood sugar in type 2 diabetics: study
Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)
June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
Abbott Labs quarterly beat overshadowed by unchanged forecast
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast
April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
Abbott Lab's first-quarter sales beat expectations
April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.
Abbott misses revenue estimates, sees lackluster first-quarter profit
Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit
Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
Abbott Labs says M&A not a high priority now
Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Abbott Labs says M&A not a high priority now
Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Abbott Lab's fourth-quarter revenue rises 2.3 pct
Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.
Estimates